Predictors of outcome in an AIEOP series of childhood ependymomas: A multifactorial analysis

Neuro-Oncology

Volumn 14, Issue 11, 2012, Pages 1346-1356

  Modena, Piergiorgio ^a   Buttarelli, Francesca R ^b   Miceli, Rosalba ^a   Piccinin, Elena ^a   Baldi, Caterina ^b   Antonelli, Manila ^a   Morra, Isabella ^c   Lauriola, Libero ^d   Di Rocco, Concezio ^d   Garrè, Maria Luisa ^e   Sardi, Iacopo ^f   Genitori, Lorenzo ^h   Maestro, Roberta ^g   Gandola, Lorenza ^f,g   Facchinetti, Federica ^g   Collini, Paola ^g   Sozzi, Gabriella ^g   Giangaspero, Felice ^b   Massimino, Maura ^g  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b POLICLINICO UMBERTO I   (Italy)

^c REGINA MARGHERITA CHILDREN S HOSPITAL   (Italy)

^d FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^e G GASLINI INSTITUTE   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h IRCCS NEUROMED   (Italy)

Author keywords

biomarker; EGFR; ependymoma; HTERT; nucleolin

Indexed keywords

CD133 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; EPIDERMAL GROWTH FACTOR RECEPTOR; MESSENGER RNA; NUCLEOLIN; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR PROTEIN; TUMOR PROTEIN 53; UNCLASSIFIED DRUG;

ARTICLE; CHILD; CHILDHOOD CANCER; CHROMOSOME 1Q; CONTROLLED STUDY; EPENDYMOMA; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOCUS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MUTATION; OVERALL SURVIVAL; PRESCHOOL CHILD; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECURRENCE FREE SURVIVAL; SCHOOL CHILD; TISSUE MICROARRAY;

ADOLESCENT; BLOTTING, WESTERN; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; EPENDYMOMA; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; INFANT; KAPLAN-MEIER ESTIMATE; MALE; PHOSPHOPROTEINS; PROGNOSIS; REAL-TIME POLYMERASE CHAIN REACTION; RNA-BINDING PROTEINS; TELOMERASE; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84868018309     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nos245     Document Type: Article

References (37)

1. Massimino M, Buttarelli FR, Antonelli M, Gandola L, Modena P, Giangaspero F. Intracranial ependymoma: factors affecting outcome. Future Oncol. 2009;5(2):207-216.
2. Kuncova K, Janda A, Kasal P, Zamecnik J. Immunohistochemical prognostic markers in intracranial ependymomas: systematic review and meta-analysis. Pathol Oncol Res. 2009;15(4): 605-614.
3. Mendrzyk F, Korshunov A, Benner A, et al. Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. Clin Cancer Res. 2006;12(7 Pt 1):2070-2079.
4. Ridley L, Rahman R, Brundler MA, et al. Multifactorial analysis of predictors of outcome in pediatric intracranial ependymoma. Neuro Oncol. 2008;10(5):675-689.
5. Tabori U, Ma J, Carter M, et al. Human telomere reverse transcriptase expression predicts progression and survival in pediatric intracranial ependymoma. J Clin Oncol. 2006;24(10):1522-1528.
6. Korshunov A, Witt H, Hielscher T, et al. Molecular staging of intracranial ependymoma in children and adults. J Clin Oncol. 2010;28(19):3182-3190.
7. Carter M, Nicholson J, Ross F, et al. Genetic abnormalities detected in ependymomas by comparative genomic hybridisation. Br J Cancer. 2002;86(6):929-939.
8. Gilbertson RJ, Bentley L, Hernan R, et al. ERBB receptor signaling promotes ependymomacell proliferation andrepresents a potentialnovel therapeutic target for this disease. Clin Cancer Res. 2002;8(10):3054-3064.
9. Tabori U, Wong V, Ma J, et al. Telomere maintenance and dysfunction predict recurrence in paediatric ependymoma. Br J Cancer. 2008;99(7):1129-1135.
10. Massimino M, Gandola L, Giangaspero F, et al. Hyperfractionated radiotherapy and chemotherapy for childhood ependymoma: final results of the first prospective AIEOP (Associazione Italiana di Ematologia-Oncologia Pediatrica) study. Int J Radiat Oncol Biol Phys. 2004;58(5):1336-1345.
11. Massimino M, Giangaspero F, Garre ML, et al. Salvage treatment for childhood ependymoma after surgery only: pitfalls of omitting "at once" adjuvant treatment. Int J Radiat Oncol Biol Phys. 2006;65(5):1440-1445.
12. Massimino M, Gandola L, Barra S, et al. Infant ependymoma in a 10-year AIEOP (Associazione Italiana Ematologia Oncologia Pediatrica) experience with omitted or deferred radiotherapy. Int J Radiat Oncol Biol Phys. 2011;80(3):807-14.
13. Miyanaga T, Hirato J, Nakazato Y. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method. Neuropathology. 2008;28(2):116-126.
14. Lualdi E, Modena P, Debiec-Rychter M, et al. Molecular cytogenetic characterization of proximal-type epithelioid sarcoma. Genes Chromo Cancer. 2004;41(3):283-290.
15. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006;1(3):1112-1116.
16. Moons KG, Donders AR, Steyerberg EW, Harrell FE. Penalized maximum likelihood estimation to directly adjust diagnostic and prognostic prediction models for overoptimism: a clinical example. J Clin Epidemiol. 2004;57(12):1262-1270.
17. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8(5):551-561.
18. Modena P, Lualdi E, Facchinetti F, et al. Identification of tumor-specific molecular signatures in intracranial ependymoma and association with clinical characteristics. J Clin Oncol. 2006;24(33):5223-5233.
19. Taylor MD, Poppleton H, Fuller C, et al. Radial glia cells are candidate stem cells of ependymoma. Cancer Cell. 2005;8(4):323-335.
20. Johnson RA, Wright KD, Poppleton H, et al. Cross-species genomics matches driver mutations and cell compartments to model ependymoma. Nature. 2010;466(7306):632-636.
21. Massimino M, Gandola L, Garre ML, et al. Do we really need class 1 evidence results to give adjuvant radiation therapy to childhood intracranial ependymomas? Childs Nerv Syst. 2009;25(6):641-2; author reply 643-4.
22. Bustin SA, Mueller R. Real-time reverse transcription PCR (qRT-PCR) and its potential use in clinical diagnosis. Clin Sci (Lond). 2005;109(4):365-379.
23. Skrzypski M. Quantitative reverse transcriptase real-time polymerase chain reaction (qRT-PCR) in translational oncology: lung cancer perspective. Lung Cancer. 2008;59(2):147-154.
24. Bustin SA, Mueller R. Real-time reverse transcription PCR and the detection of occult disease in colorectal cancer. Mol Aspects Med. 2006;27(2-3):192-223.
25. Gabert J, Beillard E, van der Velden VH, et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia. 2003;17(12):2318-2357.
26. Wu YL, Dudognon C, Nguyen E, et al. Immunodetection of human telomerase reverse-transcriptase (hTERT) re-appraised: nucleolin and telomerase cross paths. J Cell Sci. 2006;119(Pt 13): 2797-2806.
27. Dei Tos AP, Ellis I. Assessing epidermal growth factor receptor expression in tumours: what is the value of current test methods? Eur J Cancer. 2005;41(10):1383-1392.
28. Fruehauf J. EGFR function and detection in cancer therapy. J Exp Ther Oncol. 2006;5(3):231-246.
29. Masutomi K, Yu EY, Khurts S, et al. Telomerase maintains telomere structure in normal human cells. Cell. 2003;114(2):241-253.
30. Janknecht R. On the road to immortality: HTERT upregulation in cancer cells. FEBS Lett. 2004;564(1-2):9-13.
31. Kelland LR. Overcoming the immortality of tumour cells by telomere and telomerase based cancer therapeutics-current status and future prospects. Eur J Cancer. 2005;41(7):971-979.
32. Liu JP, Chen W, Schwarer AP, Li H. Telomerase in cancer immunotherapy. Biochim Biophys Acta. 2010;1805(1):35-42.
33. Croul S, Otte J, Khalili K. Brain tumors and polyomaviruses. J Neurovirol. 2003;9(2):173-182.
34. Bergsagel DJ, Finegold MJ, Butel JS, Kupsky WJ, Garcea RL. DNA sequences similar to those of simian virus 40 in ependymomas and choroid plexus tumors of childhood. N Engl J Med. 1992;326(15):988-993.
35. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Dev. 2009;18(8):1127-1134.
36. Servidei T, Meco D, Trivieri N, et al. Effects of epidermal growth factor receptor blockade on ependymoma stem cells in vitro and in orthotopic mouse models. Int J Cancer. 2012;131(5):E791-803.
37. Guan S, Shen R, Lafortune T, et al. Establishment and characterization of clinically relevant models of ependymoma: A true challenge for targeted therapy. Neuro Oncol. 2011;13(7):748-758.